Psychedelic-Assisted Therapy (Pat): A New Frontier in Mental Health Treatment

Psychedelic-assisted therapy (PAT) is a promising new approach for treating depression, PTSD, and substance use disorders. This review describes how psychedelics like psilocybin, MDMA, LSD, and ketamine work, their therapeutic uses, clinical evidence, and ethical issues. It highlights findings from recent trials (2020–2024), discusses safety and regulation debates, and notes that older adults are an underexplored population. The paper synthesizes current evidence and identifies gaps and future research priorities.

Study at a glance

Abstract

Psychedelic-assisted therapy (PAT) has emerged as a promising and innovative approach to treating a range of mental health disorders, including depression, post-traumatic stress disorder (PTSD), and substance use disorders. Once sidelined due to regulatory bans and social stigma, psychedelics such as psilocybin, 3,4-methylenedioxymethamphetamine (MDMA), lysergic acid diethylamide (LSD), and ketamine are now the focus of rigorous clinical investigation. This review explores the mechanisms of action, therapeutic applications, clinical evidence, ethical considerations, and future directions for psychedelic-assisted therapies. Although the general concepts of PAT are well described in literature, this paper highlights emerging evidence from recent trials (2020–2024), discusses ongoing debates on safety and regulation, and identifies underexplored populations such as older adults. Thus, this review contributes a contemporary synthesis focusing on evidence gaps and future research priorities.